News Releases

Date Title and Summary Additional Formats
September 29, 2022 Ayala Pharmaceuticals to Host Key Opinion Leader Webinar on Desmoid Tumors
Event will feature a review of data from part A of the Phase 2/3 RINGSIDE trial of AL102 KOL s and m anagement to p resent on Thursday, October 6 th @ 8 AM ET REHOVOT, Israel and WILMINGTON, Del., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc.
September 27, 2022 Ayala Pharmaceuticals Announces Fast Track Designation Granted by US FDA for AL102 in Progressing Desmoid Tumors
REHOVOT, Israel and WILMINGTON, Del., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers today announced
September 12, 2022 Ayala Pharmaceuticals Presents Positive Interim Data from RINGSIDE Pivotal Phase 2/3 Trial of AL102 in Desmoid Tumors at ESMO Congress 2022
- Updated interim results from Part A of RINGSIDE show first confirmed partial response (PR) achieved at week 16 and 3 additional unconfirmed PRs over the follow-up period - - Consistent early tumor shrinkage with measures deepening over time - - AL102 was well tolerated at all doses evaluated - -
August 24, 2022 Ayala Pharmaceuticals Selected to Present Efficacy and Tolerability Data on AL102 in Desmoid Tumors at the European Society for Medical Oncology (ESMO) 2022 Congress
Oral presentation will feature results from Part A of the Phase 2/3 RINGSIDE clinical study REHOVOT, Israel and WILMINGTON, Del., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule
August 15, 2022 Ayala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Interim data from Part A of the RINGSIDE study demonstrated substantial initial anti-tumor activity for AL102 as a single agent and supports continued development More advanced and comprehensive data set from RINGSIDE to be presented at ESMO REHOVOT, Israel and WILMINGTON, Del., Aug.
July 5, 2022 Ayala Pharmaceuticals Announces Interim Data from Part A of the Phase 2/3 RINGSIDE Trial of AL102 in Desmoid Tumors
- Tumor shrink ing observed in substantially all patients who were evaluable at 16 weeks - - Favorable safety results observed : AL102 was well tolerated - - Additional data to be submitted for presen t ation at a medical conference in 2H 2022 - REHOVOT, Israel & WILMINGTON, Del., July 05, 2022
June 6, 2022 Ayala Pharmaceuticals Announces Data on AL101 in Adenoid Cystic Carcinoma (ACC) at 2022 ASCO Annual Meeting
-- Presentation at ASCO features updated results from Phase 2 ACCURACY study -- -- AL101 demonstrated anti-tumor activity by achieving an overall disease control rate of 69% -- -- Patients achieving partial responses had higher progression-free survival -- REHOVOT, Israel & WILMINGTON, Del., June
June 2, 2022 Ayala Pharmaceuticals to Present at the 2022 Jefferies Global Healthcare Conference
REHOVOT, Israel and WILMINGTON, Del., June 02, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in
May 16, 2022 Ayala Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Interim data from Part A of RINGSIDE study of AL102 expected mid-2022 REHOVOT, Israel and WILMINGTON, Del., May 16, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for
April 27, 2022 Ayala Pharmaceuticals Announces Poster Presentation on AL101 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
REHOVOT, Israel and WILMINGTON, Del., April 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in
Displaying 1 - 10 of 16